SYRE Spyre Therapeutics, Inc.
$93.32▲ +0.44%
Healthcare
Other
Volume 24.3K
Avg Volume (10D) 1.16M
Key Metrics & Fundamentals
Market Cap
$8.72B
P/E Ratio
–
Div Yield
0.00%
52W Range
21.15 - 110.18
% vs 50 MA
2.38%
% vs 200 MA
29.24%
RSI-14
57.5
MACD Histogram
+1.4800
Beta (1Y vs SPY)
1.76
Free Cash Flow
-$69.88M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$121.64M
COGS
–
Operating Exp
$81.64M
Operating Income
-$81.64M
EBIT
-$81.64M
Pretax Income
-$36.20M
Net Income
-$36.20M
EPS (Diluted)
-0.43
Price & Volume History
Loading chart…
Recent News
Spyre Therapeutics (SYRE) Stock May Be Fully Priced Following New IBD Data Preview
Simply Wall St. · Oct 23, 2026 9:15 PM ET
Spyre's Ulcerative Colitis Combo Approach Gains Support From AbbVie Data, UBS Says
MT Newswires · Oct 20, 2026 12:48 PM ET
Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026
GlobeNewswire · Oct 18, 2026 9:30 AM ET
UBS Initiates Spyre Therapeutics at Buy With $120 Price Target
MT Newswires · Oct 12, 2026 7:44 AM ET
Spyre Therapeutics (SYRE) Completed A $350 Million Public Stock Offering
Simply Wall St. · Oct 8, 2026 1:15 PM ET
Update: Spyre Shares Fall After Pricing $350 Million Stock Offering
MT Newswires · Oct 6, 2026 3:56 PM ET
Spyre Therapeutics Sinks 14% on Upsized $350 Million Stock Offering Priced Below Market
TIKR · Oct 6, 2026 1:40 PM ET
Spyre Therapeutics Prices $350 Million Common Stock Offering; Shares Down Pre-Bell
MT Newswires · Oct 6, 2026 4:59 AM ET
Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock
GlobeNewswire · Oct 5, 2026 8:13 PM ET
Spyre Therapeutics stock falls on public offering launch
Investing.com · Oct 5, 2026 4:46 PM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See SYRE's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.